Paul Colvin

Paul Colvin discloses dealings in 2 companies, chiefly Syneos Health, Inc. and Pharmaceutical Product Development Inc. Over a trading history stretching from 20 May 2011 to 2 March 2021, the count stands at 23 filings.

Market trades split into 1 purchase (€43k) and 4 sales (€653k). Sales outweigh purchases by €609k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 10 share grants and 5 option exercises. So far in 2021, the count stands at no purchases and 1 sale.

Most recently, on 4 March 2021, the filings show a share grant in Syneos Health, Inc. The most recent open-market purchase was published on 23 March 2020, 2,406 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.